XXVth International Workshop on Helicobacter and related bacteria in chronic digestive inflammation and gastric cancer

Ljubljana, Slovenia
September 15 - 15, 2012

FINAL PROGRAMME
Quando lo stile alimentare necessita di una integrazione

**INDICAZIONI**

MICROCRISTALLINA, INOSITOLO, MISCELA ENZIMATICA

**INGREDIENTI:**

- Lattasi 500 ALU e pectinasi 7 ENDO-PG)*
- Estratto di Lievito (Saccharomyces cerevisiae)
- Stearina vegetale,
- antiagglomeranti:
  - Bioossido di silicio, Magnesio stearato,
  - Gomma laccata.

(*): contenente maltodestrina

**TITOLATO IN BETA-GLUCANI.

**ESTRATTO DI LIEVITO (Saccharomyces cerevisiae)

**STEARINA VEGETALE,

**MISCELA ENZIMATICA**

**STRATO FAST**

Beta-glucani da estratto di Lievito

**Sostanze ad effetto nutritivo o fisiologico Per dose giornaliera (2 compresse)**

**INFORMAZIONE NUTRIZIONALE**

- **Calorichiesta giornaliera (2 compresse):**
  - **110 mg**
  - **250 mg**

**Dose giornaliera e modalità d’uso:**

Non eccedere la dose consigliata

2 compresse al giorno durante i pasti

**Gli integratori non vanno intesi come sostituto di una dieta**

Conservare in luogo fresco ed asciutto al riparo dalla luce.

**list of exhibitors**

As per printing date

Aptalis Pharma, Houdan, France
Ewopharma d.o.o., Ljubljana-Crnuce, Slovenia
Infai GmbH, Köln, Germany
Krka d.o.o, Novo Mesto, Slovenia
Lek Pharmaceuticals d.d., Ljubljana, Slovenia
Mevi d.o.o., Maribor, SLOVENIA
Nycomed: A Takeda Company, Ljubljana, Slovenia
Pliva Ljubljana d.o.o., Ljubljana-Crnuce, Slovenia
Dear colleagues and friends,

We would like to cordially welcome you to the XXVth International Workshop on Helicobacter and related bacteria in chronic digestive inflammation in Ljubljana.

The main goal of the EHSG is to offer in its workshop the most comprehensive and distinctly interdisciplinary event on scientific updates on Helicobacter research. We look forward to your valuable contribution and to the exchange of experience and knowledge amongst colleagues from all over the world.

The European Helicobacter Study Group has endeavoured to gather a number of high profile speakers and to increase the interaction between the delegates by continously making small modifications to the schedule.

We do hope that you will enjoy both the scientific and the social side of your stay.

Welcome to Ljubljana!

Dobrodošli v Ljubljani

Bojan Tepeš
President of the Local Organising Committee

Colm A. O’Morain
President of the European Helicobacter Study Group
# TABLE OF CONTENTS

Acknowledgements ........................................................................................................................................ 2
List of Exhibitors ........................................................................................................................................ 2
Welcoming Address .................................................................................................................................... 3
Committees – Organisation .................................................................................................................. 5
Workshops of the EHSG ........................................................................................................................ 5
Location Map ........................................................................................................................................... 6
Programme at a Glance ........................................................................................................................ 7

**Scientific Programme**

- Thursday, September 13 ....................................................................................................................... 10
- Friday, September 14 ............................................................................................................................. 11
- Saturday, September 15 ......................................................................................................................... 19

Scientific Information, Poster Schedule .......................................................................................... 24

General Information .............................................................................................................................. 25
Registration Details ............................................................................................................................ 28
Networking Events ............................................................................................................................... 28
Local Organizing Committee

President
Bojan Tepeš (Ljubljana)

Members
Marko Banić (Rijeka)
Matjaž Homar (Ljubljana)
Alojz Ihan (Ljubljana)
Miroslava Katičič (Zagreb)
Borut Štabuc (Ljubljana)
Milan Stefanović (Bled)
Davor Štimac (Rijeka)
Ante Tonkič (Split)

European Helicobacter Study Group (EHSG)

President
Colm A. O’Morain, Ireland

Members
Leif P. Andersen, Denmark
Anthony Axon, United Kingdom
Lars Engstrand, Sweden
Giovanni Gasbarrini, Italy
Javier P. Gisbert, Spain
Ernst Kuipers, The Netherlands
José C. Machado, Portugal
Peter Malfertheiner, Germany
Francis Mégraud, France
Ari P. Ristimäki, Finland
Theodore Rokkas, Greece

Emeritus Members
Michel A.L. Deltenre, Belgium
Pierre Michetti, Switzerland
José M. Pajares García, Spain
Ashley B. Price, United Kingdom
Mario G. Quina, Portugal
Erik A.J. Rauws, The Netherlands
Pentti I. Sipponen, Finland
Torkel M. Wadström, Sweden

Honorary Members
Franco Bazzoli, Italy
James G. Fox, United States
David Y. Graham, United States
Adrian Lee, Australia
Barry Marshall, Australia
Guido N.J. Tytgat, The Netherlands

Corresponding Fellows
Niyaz Ahmed, India
Luis G. Vaz Coelho, Brazil
Toshio Fujioka, Japan
Hyun Chae Jung, Korea
Varocha Mahachai, Thailand
Yaron Niv, Israel
Shu Dong Xiao, China

Organising Offices

Core Agency
Vienna Medical Academy
Alser Strasse 4
A-1090 Vienna, Austria
Phone: +43 1 405 13 83 0
Fax: +43 1 407 82 74
ehsg2012@medacad.org

Technical Exhibition
MAW
Freyung 6
A-1010 Vienna, Austria
Phone: +43 1 536 63 15
Fax: +43 1 535 60 16
maw@media.co.at

Workshops of the EHSG

• Bordeaux (1988)
• Ulm (1989)
• Toledo (1990)
• Bologna (1991)
• Dublin (1992)
• Brussels (1993)
• Houston (1994)
• Edinburgh (1995)
• Copenhagen (1996)
• Lisbon (1997)
• Budapest (1998)
• Helsinki (1999)
• Rome (2000)
• Strasbourg (2001)
• Athens (2002)
• Stockholm (2003)
• Vienna (2004)
• Copenhagen (2005)
• Wrocław (2006)
• Istanbul (2007)
• Riga (2008)
• Porto (2009)
• Rotterdam (2010)
• Dublin (2011)
• Ljubljana (2012)
• Madrid (2013)

Next Workshop
Madrid, Spain, September 14-14, 2013

www.helicobacter.org
<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
</table>
| 18.00 – 19.00 hrs | **Celebration of 30 years of Helicobacter pylori**  
**The White Hall**  
The impact of the discovery of *H. pylori* on:  
Gastroenterology: A. Axon (Leeds, UK)  
Pathology: P. Sipponen (Helsinki, Finland)  
Bacteriology: F. Mégraud (Bordeaux, France) |
| 19.00 hrs    | **Welcome Reception**                          |

www.helicobacter.org
## PROGRAMME AT A GLANCE

**Friday, September 14, 2012**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>08.30 – 09.15 hrs</td>
<td><strong>Opening Conferences</strong></td>
<td><strong>Grand Union Hall</strong></td>
</tr>
<tr>
<td>09.15 – 11.00 hrs</td>
<td><strong>Symposium: Gastric microbiome</strong></td>
<td><strong>Grand Union Hall</strong></td>
</tr>
<tr>
<td></td>
<td>Methods to study the microbiome, Clara Belzer (<em>Wageningen, The Netherlands</em>)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Gastric microbiome among Korean Gastric cancer patients, Yong Chan Lee (<em>Seoul, Korea</em>)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Gastric microbiota &amp; nitrosamines, K. Sugano (<em>Jichi, Japan</em>)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>The gut microbiome of Ötzi, the ice man, L. Engstrand (<em>Stockholm, Sweden</em>)</td>
<td></td>
</tr>
<tr>
<td>11.00–11.30 hrs</td>
<td><strong>Coffee break</strong></td>
<td></td>
</tr>
<tr>
<td>11.30–13.00 hrs</td>
<td><strong>Parallel Workshops 1 – 2</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>W1 Microbiology, Molecular Genetics &amp; Virulence Factors</strong></td>
<td><strong>Grand Union Hall</strong></td>
</tr>
<tr>
<td></td>
<td><strong>W2 Epidemiology and Pediatrics</strong></td>
<td><strong>The White Hall</strong></td>
</tr>
<tr>
<td>13.00–13.30 hrs</td>
<td><strong>Lunch</strong></td>
<td></td>
</tr>
<tr>
<td>13.30–14.30 hrs</td>
<td><strong>Poster Rounds</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>P1 Microbiology, Molecular Genetics &amp; Virulence Factors</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>P2 Epidemiology, Pediatrics &amp; Diagnosis</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>P3 Inflammation &amp; Host Response, Immunity</strong></td>
<td></td>
</tr>
<tr>
<td>14.30–16.00 hrs</td>
<td><strong>Symposium: Management of patients at high risk of gastric cancer</strong></td>
<td><strong>Grand Union Hall</strong></td>
</tr>
<tr>
<td></td>
<td>Who are the high risk patients? A. Axon (<em>Leeds, UK</em>)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Histological assessment of premalignant conditions, A. Ristimäki (<em>Helsinki, Finland</em>)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Non-invasive screening for gastric cancer in Europe, A. de Vries (<em>Rotterdam, The Netherlands</em>)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Surveillance of patients at risk, M. Asaka (<em>Sapporo, Japan</em>)</td>
<td></td>
</tr>
<tr>
<td>16.00–16.30 hrs</td>
<td><strong>Coffee break</strong></td>
<td></td>
</tr>
<tr>
<td>16.30–18.00 hrs</td>
<td><strong>Parallel Workshops 3 – 4</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>W3 Inflammation and Host Response</strong></td>
<td><strong>Grand Union Hall</strong></td>
</tr>
<tr>
<td></td>
<td><strong>W4 Clinical Trials and Drug Resistance</strong></td>
<td><strong>The White Hall</strong></td>
</tr>
<tr>
<td>20.00 hrs</td>
<td><strong>EHSG Conference Dinner</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td><em>(Ticket required)</em></td>
<td></td>
</tr>
</tbody>
</table>
PROGRAMME AT A GLANCE

Saturday, September 15, 2012

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>08.30–10.00 hrs</td>
<td>Symposium: Dynamics of chronic infections</td>
</tr>
<tr>
<td></td>
<td><strong>Grand Union Hall</strong></td>
</tr>
<tr>
<td></td>
<td><em>H. pylori</em> infection and associated diseases along the centuries, A. Sonnenberg (Portland, OR, USA)</td>
</tr>
<tr>
<td></td>
<td>Dynamics of other chronic bacterial infections, D. Graham (Houston, TX, USA)</td>
</tr>
<tr>
<td></td>
<td>Changing patterns of <em>H. pylori</em> associated diseases in Asia, V. Mahachai (Bangkok, Thailand)</td>
</tr>
<tr>
<td></td>
<td>Dynamics of <em>H. pylori</em> infection in a given patient, N. Ahmed (Hyderabad, India)</td>
</tr>
<tr>
<td>10.00–10.30 hrs</td>
<td>Coffee break</td>
</tr>
<tr>
<td>10.30–12.00 hrs</td>
<td>Parallel Workshops 5 – 6</td>
</tr>
<tr>
<td></td>
<td><strong>W5 Gastric Cancer and preneoplastic lesions</strong></td>
</tr>
<tr>
<td></td>
<td><strong>Grand Union Hall</strong></td>
</tr>
<tr>
<td></td>
<td><strong>W6 Extra-Digestive Diseases and Other Helicobacters</strong></td>
</tr>
<tr>
<td></td>
<td><strong>The White Hall</strong></td>
</tr>
<tr>
<td>12.00–12.30 hrs</td>
<td>Lunch</td>
</tr>
<tr>
<td>12.30–13.30 hrs</td>
<td>Poster Rounds</td>
</tr>
<tr>
<td></td>
<td><strong>P4 Clinical Trials and Drug Resistance</strong></td>
</tr>
<tr>
<td></td>
<td><strong>P5 Gastric Cancer and preneoplastic lesions</strong></td>
</tr>
<tr>
<td></td>
<td><strong>P6 Extra-Digestive Diseases and Other Helicobacters, NSAIDs &amp; Novelties</strong></td>
</tr>
<tr>
<td>13.30–15.00 hrs</td>
<td>Symposium: <em>H. pylori</em> infection and areas of uncertainties &amp; controversies</td>
</tr>
<tr>
<td></td>
<td><strong>Grand Union Hall</strong></td>
</tr>
<tr>
<td></td>
<td><em>H. pylori</em> &amp; the oesophagus, P. Malfertheiner (Magdeburg, Germany)</td>
</tr>
<tr>
<td></td>
<td><em>H. pylori</em> &amp; the colon, T. Rokkas (Athens, Greece)</td>
</tr>
<tr>
<td></td>
<td><em>H. pylori</em> &amp; metabolic syndrome, F. Franceschi (Roma, Italy)</td>
</tr>
<tr>
<td></td>
<td><em>H. pylori</em> &amp; the brain, L. Letenneur (Bordeaux, France)</td>
</tr>
<tr>
<td>15.00–15.30 hrs</td>
<td>Aptalis Pharma Special Lecture</td>
</tr>
<tr>
<td></td>
<td><strong>Grand Union Hall</strong></td>
</tr>
<tr>
<td></td>
<td>Management of <em>H. pylori</em> treatment failures, J. Gisbert (Madrid, Spain)</td>
</tr>
<tr>
<td>15.30–16.00 hrs</td>
<td>Coffee break</td>
</tr>
<tr>
<td>16.00–17.00 hrs</td>
<td>Debate: Functional dyspepsia. What comes first: PPI or <em>H. pylori</em> eradication?</td>
</tr>
<tr>
<td></td>
<td><strong>Grand Union Hall</strong></td>
</tr>
<tr>
<td></td>
<td>PPI: J.H. Wandall (Mogeltonder, Denmark)</td>
</tr>
<tr>
<td></td>
<td><em>H. pylori</em> eradication: P. Moayyedi (Hamilton, ON, Canada)</td>
</tr>
<tr>
<td>17.00–18.00 hrs</td>
<td>Closing conference</td>
</tr>
<tr>
<td></td>
<td><strong>Grand Union Hall</strong></td>
</tr>
<tr>
<td></td>
<td>Epigenetic changes in gastric cancer, G. Nardone (Napoli, Italy)</td>
</tr>
<tr>
<td></td>
<td>Critical views on the potential benefits of <em>H. pylori</em> infection, J. Atherton (Nottingham, UK)</td>
</tr>
<tr>
<td></td>
<td><strong>Awarding of the Marshall &amp; Warren Medal to Richard Hunt, Hamilton, ON, Canada</strong></td>
</tr>
<tr>
<td>18.00–18.15 hrs</td>
<td>Presentation of the next meeting Madrid Spain</td>
</tr>
<tr>
<td></td>
<td><strong>Closing remarks</strong></td>
</tr>
<tr>
<td></td>
<td><strong>Grand Union Hall</strong></td>
</tr>
</tbody>
</table>
18.00 - 19.00 hrs  
**Celebration of 30 years of Helicobacter pylori**  
*The White Hall*

**Chair:**  
B. Tepeš (SI)  
C. O’Morain (IE)  
M. Asaka (JP)

**Speaking Time:** 20’

Recent progress in diagnosis and treatment of early gastric cancer and strategy of the impact of the discovery of *H. pylori* on:

- **Gastroenterology:** A. Axon (*Leeds, UK*)
- **Pathology:** P. Sipponen (*Helsinki, Finland*)
- **Bacteriology:** F. Mégraud (*Bordeaux, France*)

**Welcome Reception**
08.30 – 09.15 hrs  
**Opening conferences**  
*Grand Union Hall*

**Chair:** B. Tepeš (SI)  
C. O’Morain (IE)

**Speaking Time:** 17’+4’

- **Tridimensional structure if the CagA oncoprotein**  
  *M. Hatakeyama (Tokyo, Japan)*

- **Gut microbiome and its modulation by probiotics**  
  *J. Versalovic (Houston, TX, USA)*

09.15 – 11.00 hrs  
**Symposium: Gastric microbiome**  
*Grand Union Hall*

**Chair:** P. Malfertheiner (DE)  
G. Gasbarrini (IT)

**Speaking Time:** 20’+5’

- **Methods to study the microbiome**  
  *C. Belzer (Wageningen, The Netherlands)*

- **Gastric microbiome among Korean Gastric cancer patients**  
  *Y.C. Lee (Seoul, Korea)*

- **Gastric microbiota & nitrosamines**  
  *K. Sugano (Jichi, Japan)*

- **The gut microbiome of Ötzi, the ice man**  
  *L. Engstrand (Stockholm, Sweden)*

11.00 – 11.30 hrs  
**Coffee break**
11.30 – 13.00 hrs  **Workshop 1. Microbiology, Molecular Genetics & Virulence Factors**  
*Room: Grand Union Hall*

**Chair:** S. Jeverica (SI)  
J. Versalovic (US)

**Speaking time:** 12'+3'

**W1.1**  
**Prevalence and clinical significance of homA and homB, two novel *Helicobacter pylori* virulence markers, in Slovenian paediatric population**  
A. Šterbenc¹, M. Homan², B. J. Kocjan¹, B. Luzar³, N. Zidar³, M. Poljak¹⁵;  
¹Institution of Microbiology and Immunology, Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia, ²Department of Gastroenterology, Hepatology and Nutrition, University Children’s Hospital, Ljubljana, Slovenia, ³Institute of Pathology, Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia.

**W1.2**  
**Identification of protein-protein interactions in the TFS4 type IV secretion system of *Helicobacter pylori***  
M. N. Alandiyjany, J. I. Grove, R. M. Delahay;  
Centre for Biomolecular Sciences and Nottingham Digestive Diseases Centre, University of Nottingham, Nottingham, United Kingdom.

**W1.3**  
**Screening of prophage sequences among *Helicobacter pylori* isolates**  
A. Timóteo¹², S. Breurec³, M. Oleastro⁴, M. Roxo-Rosa⁴⁵, J. M. B. Vítor⁶, P. Lehours⁷, F. F. Vale⁷;  
¹Faculdade de Engenharia - Universidade Católica Portuguesa, Sintra, Portugal, ²Faculdade de Ciências - Universidade de Lisboa, Lisboa, Portugal, ³Pasteur Institut Dakar Sénégal, Dakar, Senegal, ⁴Instituto Nacional de Saúde Dr Ricardo Jorge, Lisboa, Portugal, ⁵BioFIG, Lisboa, Portugal, ⁶iMed. Faculdade de Farmácia - Universidade de Lisboa, Lisboa, Portugal, ⁷INSERM U853, Bordeaux, France.

**W1.4**  
**Gene polymorphisms of microRNAs in *Helicobacter pylori*-induced high risk atrophic gastritis and gastric cancer**  
J. Kupcinskas¹, T. Wex², R. Steponaitiene¹, S. Juženas¹, M. Leja¹, G. Kudelis¹, L. Jonaitis¹, J. Skiecevičienė¹;  
¹Lithuanian University of Health Sciences, Kaunas, Lithuania, ²Clinic of Gastroenterology, Hepatology and Infectious Diseases, Otto von Guericke University, Magdeburg, Germany, ³Faculty of Medicine, University of Latvia, Digestive Diseases Center, Riga, Latvia.

**W1.5**  
**Variation in *Helicobacter pylori cagA* promoter region is associated with CagA expression**  
R. M. Ferreira¹², J. C. Machado¹², C. Figueiredo¹²;  
¹IPATIMUP - Institute of Molecular Pathology and Immunology of the University of Porto, Porto, Portugal, ²Faculty of Medicine of the University of Porto, Porto, Portugal.

**W1.6**  
**Functional characterisation of a VirD2-like relaxase component of a novel Type IV secretion system in *Helicobacter pylori***  
J. I. Grove, R. M. Delahay;  
Centre for Biomolecular Sciences and Nottingham Digestive Diseases Centre, University of Nottingham, Nottingham, United Kingdom.

13.00 – 13.30 hrs  **Lunch**
11.30 – 13.00 hrs  Workshop 2. Epidemiology and Pediatrics  
*The White Hall*

**Chair:**
M. Homan (SI)
L.V. Coelho (BR)

**Speaking time:** 12’+3’

**W2.1** Incidence of *Helicobacter pylori* infection in children during a one-year follow-up and the infection status in families in a rural area of Japan.  
*M. Okuda*¹, S. Kikuchi², T. Osaki³, K. Yagyu², Y. Lin², K. Maekawa¹, H. Yonezawa³, S. Kamiya³, Y. Fukuda¹;

1Department of General Medicine and Community Health Science, Hyogo Medical College of Medicine, Sasayama, Japan, 2Department of Public Health, Aichi Medical University School of Medicine, Nagakute, Japan, 3Department of Infectious Diseases, Kyorin University School of Medicine, Mitaka, Japan.

**W2.2** A population-based endoscopic survey of *Helicobacter pylori* infection in Myanmar  
*V. Mahachai*¹, T. Myint², T. Swe³, T. May³, T. Uchida⁴, T. Fujioka³, Y. Yamaoka⁶, R. Vilaichone⁷;

1Division of Gastroenterology, Department of Medicine, Chulalongkorn University Hospital, Bangkok, Thailand, 2Department of Medicine, Yangon General Hospital, Yangon, Myanmar, 3Novel Square Medical Clinic, Yangon, Myanmar, 4Department of Molecular Pathology, Oita University, Oita, Japan, 5Department of Gastroenterology, Oita University, Oita, Japan, 6Department of Medicine-Gastroenterology, Oita University, Oita, Japan, 7Gastroenterology Unit, Department of Medicine, Thammasat University Hospital, Pathumthani, Thailand.

**W2.3** Nationwide mortality in duodenal and gastric ulcers; a 40-year follow-up.  
*T. U. Kosunen*¹, E. Pukkala², H. Rautelin¹,³;

1University of Helsinki, Helsinki, Finland, 2Finnish Cancer Registry, Helsinki, Finland, 3University of Uppsala, Uppsala, Sweden.

**W2.4** Pre-neoplastic lesions in gastric biopsies of children are not dependent on infection with cagA, vacA, iceA and babA2 strains  
*M. Homan*¹, B. J. Kocjan², A. Sterbenc², B. Luzar³, N. Zidar³, R. Orel², M. Poljak²;

1University Children’s Hospital, Ljubljana, Slovenia, 2Institute of Microbiology and Immunology, Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia, 3Institute of Pathology, Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia.

**W2.5** Dyspepsia and *H. pylori* infection: a 15 years study.  
*N. Dal Bó*¹, *F. Ferrara*¹, T. Slonго¹, S. Loperfido¹, A. Caroli¹, R. Marcello¹, H. Heras Salvat¹, A. Schiavinato¹, C. Scarpiagnato², F. Di Mario¹;

1Department of Internal Medicine, Gastroenterology Unit, Treviso General Hospital, Treviso, Italy, 2Department of Clinical Sciences, Laboratory of Clinical Pharmacology, University of Parma, Parma, Italy.

**W2.6** Novel immuno-line system to detect infections with pathogenic *H. pylori*  
*G. Goettner*¹, L. Formicella¹, L. Romberg², C. Bolz², C. Nölting¹, E. Soutschek¹, M. Gerhard²;

1Mikrogen GmbH, Neuried, Germany, 2Institute for Microbiology, Immunology and Hygiene, Technical University, Munich, Germany.

13.00 – 13.30 hrs  Lunch
Programme Friday, September 14

13.30 – 14.30 hrs  Poster Rounds
Room: The Garden Hall

The following posters will be discussed with the authors

**Poster Round 1:** Microbiology, Molecular Genetics & Virulence Factors
Chair:
P1.01 - P1.15: L. Engstrand (SE)
N. Ahmed (IN)
P1.16 - P1.28: S. Jeverica (SI)
J. Versalovic (US)

**Poster Round 2:** Epidemiology, Pediatrics & Diagnosis
Chair:
P2.01 - P2.15: P. Moayyedi (CA)
A. Sonnenberg
P2.16 - P2.30: M. Homan (SI)
L.V. Coelho (BZ)
P2.31 - P2.46: F. Franceschi (IT)
V. Machachai (TH)

**Poster Round 3:** Inflammation and Host Response
P3.1 - P3.8: A. Ihan (SI)
L.P. Andersen (DK)
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>14.30 – 16.00 hrs</td>
<td>Symposium: Management of patients at high risk of gastric cancer</td>
</tr>
<tr>
<td></td>
<td><em>Grand Union Hall</em></td>
</tr>
<tr>
<td></td>
<td>Chair: Y.C. Lee (KR)</td>
</tr>
<tr>
<td></td>
<td>B. Štabuc (SI)</td>
</tr>
<tr>
<td></td>
<td>Speaking Time: 17’+4’</td>
</tr>
<tr>
<td></td>
<td><strong>Who are the high risk patients?</strong> A. Axon (Leeds, UK)</td>
</tr>
<tr>
<td></td>
<td><strong>Histological assessment of premalignant conditions</strong> A. Ristimaki (Helsinki, Finland)</td>
</tr>
<tr>
<td></td>
<td><strong>Non-invasive screening for gastric cancer in Europe</strong> E. Kuipers (Rotterdam, The Netherlands)</td>
</tr>
<tr>
<td></td>
<td><em>Surveillance of patients at risk</em> M. Asaka (Sapporo, Japan)</td>
</tr>
<tr>
<td>16.00 – 16.30 hrs</td>
<td><strong>Coffee break</strong></td>
</tr>
</tbody>
</table>
16.30 – 18.00 hrs  Workshop 3. Inflammation and Host Response  
**Grand Union Hall**

**Chair:** A. Ihan (SI)  
L.P. Andersen (DK)

**Speaking Time:** 12’+3’

**W3.1**  IL-8 response of dendritic cells to *Helicobacter pylori* is determined by strain specific LPS  
*A. N. Kopitar*, M. Skvarč, J. Kos, B. Tepeš, A. Ihan;  
University of Ljubljana, Medical Faculty Ljubljana, Institute of Microbiology and Immunology, Ljubljana, Slovenia,  
University of Ljubljana, Faculty of Pharmacy, Department of Pharmaceutical Biology, Ljubljana, Slovenia,  
Abakus Medico Health Centre Rogaska, Rogaska Slatina, Slovenia.

**W3.2**  Involvement and source of B-cells activating factor(s) in *H. pylori*-associated diseases  
*M. de Bernard*1,2, *F. Munari*2, *M. Fassan*1, *M. A. Cassatella*3;  
University of Padova, Padova, Italy,  
Venetian Institute of Molecular Medicine, Padova, Italy,  
University of Verona, Verona, Italy.

**W3.3**  Mucin expression in *Helicobacter pylori* associated gastric ulcer disease  
*Y. Niv*, S. Ho;  
Rabin Medical Center, Tel Aviv University, Petach Tikva, Israel,  
UCSD, VA Medical Center, San Diego, CA, United States.

**W3.4**  Myeloid differentiation primary response gene 88 (MyD88) signaling is protective during Helicobacter-induced gastric cancer  
*K. S. Doran*, E. M. Carmona, A. Banerjee, *M. Obonyo*;  
San Diego State University, San Diego, CA, United States,  
University of California, San Diego, La Jolla, CA, United States.

**W3.5**  The Hypoxia Induced Factor 1 is Involved in *Helicobacter pylori*-Induced Pro-Inflammatory Response of Gastric Epithelial Cells in Vitro  
*C. Varon*, K. Rouault, L. Chambonnier, M. Sineux, M. Gourmelin, M. Coultheinx, F. Mazurier;  
INSERM U853, Bordeaux, France,  
INSERM U1035, Université Bordeaux Segalen, Bordeaux, France.

**W3.6**  The effect of *H. pylori* density on gastric stem cells and gastric mesenchymal stem cells  
*M. Ugras*, M. Tosun, F. Aktepe;  
Yeditepe University Medical Faculty Department of Pediatrics, Istanbul, Turkey,  
Afyon Kocatepe Univ Medical Faculty, Department Histology and Embriology, Afyonkarahisar, Turkey,  
Afyon Kocatepe Univ Medical Faculty, Department of Pathology, Afyonkarahisar, Turkey.

20.00 hrs  EHSO Conference Dinner (Ticket required)
16.30 – 18.00 hrs

**Workshop 4. Clinical Trials and Drug Resistance**

*The White Hall*

**Chair:** T. Filipec Kanizaj (HR)

**Speaking Time:** 12’+3’

**Room:**

16.30 – 18.00 hrs Workshop 4. Clinical Trials and Drug Resistance

---

**W4.1**

Tripletherapy guided by molecular detection of antibiotic resistances versus standard tripletherapy for *Helicobacter pylori* infection: a randomised trial

J. Delchier1, S. Bastuji-Garin1, L. Deforges1, X. Dray2, V. Ozenne2, L. Raskine2, F. Mion1, C. Roure-Sobas3, F. Zeribib, F. Méraud4, T. Barrioz1, A. Chryssostalis2, J. Raymond3, G. Buzaglo8, M. Nicolas-Chanoine8, S. Elia2, I. Podgajen2, S. Doumet6, J. Breuil5, S. Nahon11, A. Mangeot11, F. Grattard11, E. Cambau13, C. Burucoa1;

1Hôpital Henri Mondor, Créteil, France, 2Hôpital Lariboisière, Paris, France, 3CHU Lyon, Lyon, France, 4CHU Bordeaux, Bordeaux, France, 5CHU Lyon, Bordeaux, France, 6CHU poitiers, Poitiers, France, 7Hôpital Cochin, Paris, France, 8Hôpital Beaujon, Clichy, France, 9Hôpital EGP, Paris, France, 10Hôpital Villeneuve Saint Georges, Villeneuve Saint Georges, France, 11Hôpital Monfertmeil, Monfertmeil, France, 12CHU Saint Etienne, Saint Etienne, France, 13Hôpital Saint Louis, Paris, France.

---

**W4.2**

Phase IV, prospective, randomized and comparative study between sequential and concomitant therapy for *Helicobacter pylori* eradication in routine clinical practice. Preliminary results.


1La Princesa University Hospital, Madrid, Spain, 2CIBERehd, Barcelona, Spain, 3Hospital San Pedro de Alcántara, Cáceres, Spain, 4Hospital Ntra. Sra. Virgen de Valme, Sevilla, Spain, 5Hospital Universitario Río Hortega, Valladolid, Spain, 6Hospital Clinico Universitario ‘Lozano Blesa’, Zaragoza, Spain, 7Hospital de Sabadell, Sabadell, Spain, 8Hospital de Cabueñes, Gijon, Spain, 9Hospital de San Jorge, Huesca, Spain, 10Hospital del Mar, Barcelona, Spain, 11Hospital Costa del Sol, Malaga, Spain, 12Hospital Mutua de Terrassa, Terrassa, Spain, 13CAIBER, Madrid, Spain.

---

**W4.3**

Sequential and Quadruple Therapies for *Helicobacter pylori* Eradication Compared with Triple Therapy in Slovenia: A Multicenter,Prospective, Randomized, Controlled Trial

B. Tepes1, M. Vujasinovic2, M. Seruga3, M. Stefanovic3, S. Jeverica3;

1AM DC Rogaska, Rogaska Slatina, Slovenia, 2Bolnica Slovenj Gradec, Slovenj Gradec, Slovenia, 3Bolnica Murska Sobota, Murska Sobota, Slovenia, 4DC Bled, Bled, Slovenia, 5Institute of Microbiology and Immunology MF Ljubljana, Ljubljana, Slovenia.

---

**W4.4**

Comparison of three third-line rescue triple regimes for *Helicobacter pylori* infection in Japan


Hamamatsu University School of Medicine, Hamamatsu, Japan.

---

**W4.5**

Antimicrobial resistance of *Helicobacter pylori* isolates in Alaska Native persons from 2000-2011: results from the Alaska Sentinel Surveillance Project

M. Bruce1, J. Morris1, D. Bruden1, A. Reasonover1, D. Hurlbut1, B. McMahon2;

1CDC, Anchorage, AK, United States, 2Alaska Native Tribal Health Consortium, Anchorage, AK, United States.

---

**W4.6**

Time trends in the choice of *H.pylori* rescue treatments after one or two failures of standard PPI-clarithromycin/metronidazole containing therapy in Referral Centre for *H.pylori* in Zagreb, Croatia

M. Katicic1, T. Filippec Kanizaj1, A. Mrzljak1, M. Prskalo1, B. Skurla1, T. Borcic1, T. Bradic1, N. Sobocan1, V. Maricic2, S. Naumovski Mihalic2, V. Colic Cvrtje2;

1University Hospital Merkur, Zagreb, Croatia, 2Pliva, Pharmaceutical Industry, Zagreb, Croatia.

---

20.00 hrs

**EHSG Conference Dinner** *(Ticket required)*

www.helicobacter.org
PROGRAMME SATURDAY, SEPTEMBER 15

08.30 – 10.00 hrs  Symposium: Dynamics of chronic infections
Room:  Grand Union Hall
Chair:  M. Banić (HR)
        K. Sugano (JP)
Speaking Time:  17’+4’

H. pylori infection and associated diseases along the centuries
A. Sonnenberg (Portland, OR, USA)

Dynamics of other chronic bacterial infections
D. Graham (Houston, TX, USA)

Changing patterns of H. pylori associated diseases in Asia
V. Mahachai (Bangkok, Thailand)

Dynamics of H. pylori infection in a given patient
N. Ahmed (Hyderabad, India)

10.00 – 10.30 hrs  Coffee Break
10.30 – 12.00 hrs  Workshop 5. Gastric Cancer and preneoplastic lesions
   Room:  Grand Union Hall

Chair:  A. de Vries (NL)
        B. Štabuc (SI)

Speaking Time:  12'+3'

W5.1  The angulus biopsy is critical in the histological assessment of premalignant gastric conditions in the stomach
   M. Varbanova, T. Wex, D. Kuester, P. Malfertheiner;
   Department for Gastroenterology, Hepatology and Infectious Diseases, Magdeburg, Germany.

W5.2  The gene expression of the Wnt-modulator RACGAP1 is downregulated in H. pylori positive patients with gastric cancer.
   J. Bornschein¹, J. Nielitz¹, M. Selgrad¹, I. Drozdov², D. Kuester³, T. Wex³, P. Malfertheiner³;
   ¹Department of Gastroenterology, Hepatology and Infectious Diseases, Magdeburg, Germany, ²King's College London, BHF Centre of Excellence, Cardiovascular Division, London, United Kingdom,
   ³Department of Pathology, Magdeburg, Germany.

W5.3  Attenuated Helicobacter pylori-associated gastric cancer in Fat-1 transgenic mice producing ω-3 PUFA
   K. Hahm¹, E. Kim¹, H. Hong¹, Y. Han¹, T. Park¹, J. Kang²;
   ¹Gachon University of Medicine, Incheon, Korea, Republic of, ²Harvard Medical School, Boston, MA, United States.

W5.4  Effect of eradication of Helicobacter pylori on recurrence after endoscopic mucosal resection of gastric adenoma and early gastric cancer
   University of Ulsan, Asan Medical Center, Seoul, Korea, Republic of.

W5.5  Validation of gastritis OLGA-staging system for gastric cancer risk in a region of high prevalence: a case-control study
   I. Choi, S. Cho, M. Kook, C. Kim, J. Lee, B. Nam;
   National Cancer Center, Goyang, Korea, Republic of.

W5.6  Only minority of gastric adenocarcinomas present with decreased pepsinogen levels
   M. Leja¹23, G. Ancans¹2, I. Lasina¹, I. Liepniece-Karele¹2, D. Rudzite¹2, A. Sivins¹2, R. Skapars¹2, K. Purmalis¹, J. Eglitis¹2, I. Daugule¹;
   ¹University of Latvia, Riga, Latvia, ²Riga East University hospital, Riga, Latvia, ³Digestive Diseases Centre GASTRO, Riga, Latvia.

12.00 – 12.30 hrs  Lunch
10.30 – 12.00 hrs  Workshop 6. Extra-Digestive Diseases and Other Helicobacters
  
  Room: The White Hall
  
  Chair: A. Axon (UK)  
  F. Franceschi (IT)
  
  Speaking time: 12'+3'

W6.1  
A lentivirus based strategy for expressing the cytolethal distending toxin B subunit of *Helicobacter pullorum* - a promising alternative to study the effects of this particular genotoxin

I. Mocan¹,², C. Varon¹,², B. Mihi³,², C. Péré¹,², F. Mégraud², D. Laharie¹,², A. Ménard¹,²; ¹INSERM U853, Bordeaux, France, ²Laboratoire de Bactériologie, Université Bordeaux Segalen, Bordeaux, France.

W6.2  
Antibodies anti-CagA cross react with trophoblast cells: a risk factor for pre-eclampsia?

F. Franceschi¹, N. Di Simone², D. Roccarina¹, A. Tortora¹, S. D’ippolito², R. Castellani², F. Di Nicuolo², G. Gasbarrini², Y. Yamaoka², T. Todros², G. Scambia², A. Gasbarrini²; ¹Internal Medicine, Catholic University, Rome, Italy, ²Gynecology and Obstetrics, Catholic University, Rome, Italy.

W6.3  
Colonization capacity of *Helicobacter heilmannii* sensu stricto strains in a Mongolian gerbil model

M. H. Joosten, A. Smet, F. Pasman, R. Ducatelle, F. Haesebrouck;  
Department of Pathology, Bacteriology and Avian Diseases, Faculty of Veterinary Medicine, Ghent University, Merelbeke, Belgium.

W6.4  
Could gastric Helicobacters other than *H. pylori* be of significance in idiopathic parkinsonism?

S. M. Dobbs¹,²,³, A. Smet⁴, B. Flahou⁴, R. Dobbs¹,²,³, A. Savio⁴, A. Charlett⁴, C. Weller⁴, A. J. Lawson⁴, D. Taylor²,³, I. Bjarnason¹, F. Pasman⁴, R. Ducatelle⁴, F. Haesebrouck⁴; ¹Department of Gastroenterology, King’s College Hospital, London, United Kingdom, ²Pharmaceutical Science, King’s College London, United Kingdom, ³The Maudsley Hospital, London, United Kingdom, ⁴Department of Pathology, Bacteriology and Avian Diseases, Faculty of Veterinary Medicine, Ghent University, Merelbeke, Belgium, ⁵Reparto di Anatomia Patologica, Fondazione Poliambulanza Istituto Ospedaliero, Brescia, Italy, ⁶Statistics Unit, Centre for Infections, Health Protection Agency, London, United Kingdom, ⁷Laboratory of Gastrointestinal Pathogens, Centre for Infections, Health Protection Agency, London, United Kingdom.

W6.5  
*Helicobacter pullorum* - A potential gastrointestinal pathogen?

A. Sirianni¹, N. O. Kaakoush¹, M. Raffery¹, H. M. Mitchell¹; ¹School of Biotechnology and Biomolecular Sciences, University of New South Wales, Sydney, Australia, ²Biomedical and Mass Spectrometry, University of New South Wales, Sydney, Australia.

W6.6  
Genomics and microevolution dynamics of human-derived *Helicobacter bizzozeronii*

T. Schott, P. K. Kondadi, M. Hänninen, M. Rossi;  
Faculty of Veterinary Medicine, University of Helsinki, Helsinki, Finland.

12.00 – 12.30 hrs  Lunch
PROGRAMME SATURDAY, SEPTEMBER 15

12.30 – 13.30 hrs

**Poster Rounds**

*Room: The Garden Hall*

The following posters will be discussed with the authors

**Poster Round 4:** Clinical Trials and Drug Resistance

*Chair:*

P4.01 - P4.16: D.Y. Graham (US)
C. Belzer (NL)

P4.17 - P4.33: M. Leja (LV)
F. Bazzoli (IT)

P4.34 - P4.49: T. Filipec Kanizaj (HR)
Y. Niv (IL)

**Poster Round 5:** Gastric Cancer and preneoplastic lesions

*Chair:*

P5.01 - P5.12: A. Ristimäki (FI)
J.C. Machado (PT)

P5.13 - P5.25: A. de Vries (NL)
B. Štabuc (SI)

**Poster Round 6:** Extra-Digestive Diseases and Other Helicobacters

*Chair:*

P6.01 - P6.09: A. Gasbarrini (IT)
F. Mégraud (FR)

P6.10 - P6.18: A. Axon (UK)
F. Franceschi (IT)

13.30 – 15.00 hrs

**Symposium: H. pylori infection and areas of uncertainties & controversies**

*Room: Grand Union Hall*

*Chair:*

J. Atherton (UK)
D. Štimac (HR)

*Speaking Time: 17’+4’*

**H. pylori & the oesophagus**

*P. Malfertheiner (Magdeburg, Germany)*

**H. pylori & the colon**

*T. Rokkas (Athens, Greece)*

**H. pylori & metabolic syndrome**

*F. Franceschi (Roma, Italy)*

**H. pylori & the brain**

*L. Letenneur (Bordeaux, France)*
15.00 – 15.30 hrs  
**Aptalis Pharma Special Lecture**  
*Grand Union Hall*

**Chair:**  
T. Rokkas (GR)  
A. Tonkić (HR)

**Management of Helicobacter pylori treatment failure**  
J. Gisbert (Madrid, Spain)

15.30 – 16.00 hrs  
**Coffee break**

16.00 – 17.00 hrs  
**Debate: Functional dyspepsia. What comes first: PPI or *H. pylori* eradication?**  
*Grand Union Hall*

**Chair:**  
R. Hunt (CA)  
M. Katičič (HR)

**Speaking Time:** 25'+5'

**PPI:** J.H. Wandall, (Mogeltonder, Denmark)

**H. pylori:** Paul Moayyedi (Hamilton, ON, Canada)

17.00 – 18.00 hrs  
**Closing Conference**  
*Grand Union Hall*

**Chair:**  
J. Gisbert (ES)  
M. Stefanovič (US)

**Speaking Time:** 17'+3'

**Epigenetic changes in gastric cancer**  
G. Nardone (Napoli, Italy)

**Critical views on the potential benefits of *H. pylori* infection**  
J. Atherton (Nottingham, UK)

**Awarding of the Marshall & Warren Medal to Richard Hunt, Hamilton, ON, Canada**

18.00 – 18.15 hrs  
**Presentation of the next meeting in Madrid (J. Gisbert)**  
**Closing remarks**  
*Grand Union Hall*

**Chair:**  
C. O'Morain (IE)  
F. Mégraud (FR)
Oral Presentations

Speaking Time
The chairpersons of your session will be strict in allowing no more than the time allotted to your paper. Remember to allow some time for the changeover of speakers and chairperson’s introduction, and for questions and discussion. Make yourself known to the chairpersons and/or the technician in your session room before the beginning of the session.

Projection and Technical Setting
All rooms are equipped with a (Windows) PC and data projector for Power Point presentation only.

Handing in Your Presentation:
It must then be handed over to the technician in a break at least 1 hour before your talk either via USB-Memory Stick or CD-Rom (30’ for the talks the first morning sessions).

Presentation Format - Technical Issues:
The lecture rooms are exclusively equipped with Windows-PCs (no Macintosh machines). Please bring a CD-ROM, or floppy disk, formatted for Windows® (PC). You may want to carry a second disk or a USB-memory stick as a back-up in case there is any technical problem.
File Format: Microsoft® Power Point™ presentation formatted for Windows® (PC) only. (Operating system: Windows XP®). Maximum Resolution: XGA (1024 x 768 pixel)

Poster Presentations

ATTENTION: Posters are on display for one day only. Posters need to be taken off by the author at the end of the day. Poster not removed until then will be removed by the staff. Posters will be discarded, and neither kept or sent to the authors. Please note that the organisers cannot assume any liability for loss, theft or damage of posters displayed in the poster area.

You will find your poster board number in the author index of the abstract book, which you have received at the registration desk.

The presence at the poster of one of the authors is mandatory during the following times:

Friday, September 14, 2012, 13.30 – 14.30 hrs
Poster Round 1: Microbiology, Molecular Genetics & Virulence Factors
Poster Round 2: Epidemiology, Pediatrics & Diagnosis
Poster Round 3: Inflammation and Host Response

Mounting of the posters in Rounds 1-3 is possible on Friday, September 14, 2012 from 8.00 hrs
Removal on Friday, September 14, 2012, from 16.30 hrs.

Saturday, September 15, 2012, 12.30 – 13.30 hrs
Poster Round 4: Clinical Trials and Drug Resistance
Poster Round 5: Gastric Cancer and preneoplastic lesions
Poster Round 6: Extra-Digestive Diseases and Other Helicobacters

Mounting of the posters in Rounds 4-6 is possible on Saturday, September 15, 2012 from 8.00 hrs
Removal on Saturday, September 15, 2012, from 15.30 hrs.

Format
The usable surface on the poster board is 90 cm width x 150 cm height (portrait format). Adhesive material will be made available.
GENERAL INFORMATION

In alphabetical order.

**Badges**
Participants should collect name badges from the conference registration desks. As only registered participants will be permitted to attend the Scientific Sessions, the Exhibition and poster areas, you are kindly asked to wear your badge when entering the congress venue.

**Cancellations and Refunds**
Notice of cancellation had to be made in writing by registered letter or fax to the Congress Office. The policy for refunding registration fees is as follows:
Written cancellation received:
- Before August 15, 2012: 75% refund
- After August 15, 2012: no refund
The date of the postmark or fax ID is the basis for considering refunds. Refunds will be made after the congress.

**Certificate of Attendance**
Confirmations of attendance will be issued at the registration desk.

**Cash Dispensers**
ATMs are widely available in Ljubljana. Local currency (Euro) can also be obtained from banks and exchange bureaus.

**CME Credits**
The “XXVth International Workshop on Helicobacter and Related Bacteria in Chronic Digestive Inflammation and Gastric Cancer” was granted **12 European CME credits** (ECMEC) by the European Accreditation Council for Continuing Medical Education (EACCME).

**Coffee Breaks and Lunch**
During the session breaks refreshments (coffee, tea, and water) will be served free of charge to participants wearing name badges. Lunch tickets for Friday and Saturday had to be pre-ordered and cannot be purchased on site. Price per day: EUR 14.-. Lunch tickets are not refundable.

**Congress Venue**
GRAND HOTEL UNION, d.d.
Miklošičeva cesta 1
1000 Ljubljana, SLOVENIJA
Web: www.gh-union.si
Map: Grand Union Hotel

**Currency**
The official currency of Ireland is the Euro (EUR),
1 EUR = 1,25 USD = 0,79 GBP = 98,64 JPY = 1,20 CHF = 8,34 SEK = 7,45 DKK
as per date of printing.

**Electricity Supply**
220V - 50Hz; C & F, plugs type C, E & F (European Standard Schuko). Connectors can be obtained from your hotel reception or electronic stores.

**GSM cell phone roaming**
GSM cell/mobile phone roaming is available without any problems for all major international providers. It is advisable to inquire beforehand at your provider which roaming company in Slovenia offers the cheapest tariff.

**Internet**
You will find Internet cafés throughout the city. WIFI is available, please receive a ticket with the code at the hotel reception.
GENERAL INFORMATION

Language
The official language of the congress is English (no simultaneous translation).

Liability
In registering for the EHSG 2012 participants agree that neither the organising committee nor the congress office assume any liability whatsoever. Participants are requested to make their own arrangements in respect of health and travel. Furthermore, the organisers cannot assume any liability for changes in the programme due to external or unforeseen circumstances and force majeure.

Opening hours of the registration desk at the Congress Centre
Thursday, September 13, 2012:  14.00 – 19.00 hrs
Friday, September 14, 2012:  08.00 – 18.00 hrs
Saturday, September 15, 2012:  08.00 – 18.15 hrs

Poster Removal
The organisers cannot assume any liability for loss or damage of posters displayed in the poster area. Posters that were not removed after the end of the respective day of display, will be removed and will not be kept or mailed to the author after the meeting.

Presentations
All presenters should hand in their electronic presentation to the technician in a break at least 1 hour before the start of the session (30 minutes for the talks of the first morning sessions).

Safety - Crime
Visitor safety is generally adequate, like in any other major European city. You can walk everywhere using common sense. Pick pocketing in heavily visited tourist zones or in public transport lines might be a concern.
Unfortunately experience has shown that some basic precautionary measures should always be kept in mind in any city:
- Do not carry important items like flight tickets, passports etc. with you when visiting the conference or strolling through the city, leave them in the hotel safe during your stay. Rather carry a Xerox copy of your passport or an identity card with you.
- Try not to carry all documents, money, credit cards and other essential items and valuables in one bag. If it is lost or stolen, everything will be gone and might be difficult to replace on short notice, especially passports and visa to return to your country of residence.
- Take off your name badge when leaving the conference venue, it will make you easily identifiable as a tourist.

Smoking Policy
The EHSG 2012 Workshop is a “No-smoking-Conference”.

Staff
If you should have any questions, the congress staff will be pleased to help you.

Travel - How to travel from the Airport to Ljubljana Center
Bus
There are frequent bus connections to the Slovenian main railway station in Ljubljana. The price is 4.10 EUR. The journey time is approximately 45 minutes. Tickets are purchased on the bus.
Please find more information on  http://www.lju-airport.si/eng/passanger-visitors/getting-here/bus-and-shuttle

Taxi
A taxi rank is right in front of the airport terminal. Taxis are available according to the actual arrivals of flights. A fare from the Airport to Ljubljana City costs approximately 39 EUR (depending on the desired destination of the trip).

The company recommended by Grand Union Hotel:
ORBITA d.o.o.,
Kamniška 49,
SI-1217 Vodice, Slovenia
tel: +386 40 88 77 66,
+386 40 88 77 55
web: http://www.orbita.si,
email: info@orbita.si
Weather in Ljubljana

September in Ljubljana

- Average temperature: 17°C / 63°F
- Average high: 22°C / 72°F
- Average low: 12°C / 54°F
- Average rainfall: 37 mm / 1.5 in
REGISTRATION DETAILS

Registration Fees

<table>
<thead>
<tr>
<th></th>
<th>Before July 15, 2012</th>
<th>After July 15, 2012 and on site</th>
</tr>
</thead>
<tbody>
<tr>
<td>Regular Participants</td>
<td>EUR 300.–</td>
<td>EUR 400.–</td>
</tr>
<tr>
<td>Young Scientists (&lt;35 years)</td>
<td>EUR 150.–</td>
<td>EUR 200.–</td>
</tr>
<tr>
<td>Students (&lt;30 years)</td>
<td>EUR 100.–</td>
<td>EUR 100.–</td>
</tr>
<tr>
<td>Company Representatives</td>
<td>EUR 450.–</td>
<td>EUR 550.–</td>
</tr>
<tr>
<td>Day Ticket</td>
<td>-</td>
<td>EUR 200.–</td>
</tr>
<tr>
<td>Networking Evening</td>
<td>EUR 50.–</td>
<td>EUR 50.–</td>
</tr>
</tbody>
</table>

Payment of Registration fees may be made either cash in Euro or by Credit Card (Diners Club, Mastercard and Visa).

Please note
The reduced registration fee was only applicable, if it has been credited to the congress account before the deadline. Registering before July 15, 2012 without performing an actual payment was not sufficient to benefit from the reduction.

What is covered by the registration fee?
• Admission to all scientific sessions and the exhibition
• Admission to the networking mixer
• Abstract book and programme
• 1 copy of “Year in Helicobacter 2012”
• Refreshments during coffee breaks

Cancellations
Notice of cancellation must have been made in writing by email or fax to the Congress Office. The date of the email/fax ID was the basis for considering refunds. Registration fees may be refunded after the workshop as follows:
- Cancellation received before August 15, 2012: 75% refund
- after August 15, 2012: no refund

SOCIAL EVENTS

Thursday, September 13, 2012
Networking Mixer at the conference center.
Free for registered participants, however registration for this event is mandatory.

Friday, September 14, 2012, 20.00 hrs
EHSG Networking Evening
Price: EUR 50.–